Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol

Introduction Atypical antipsychotics have been studied to treat autism spectrum disorder (ASD). However, like little is known about whether these drugs are effective and safe when compared in controlled and non-controlled settings. This study aims to assess the efficacy and safety of second-generation antipsychotics in ASD in randomised controlled trials (RCT) and observational studies. Methods and analysis This systematic review will include RCT and prospective cohorts evaluating second-generation antipsychotics in people 5 years and older diagnosed with ASD. Searches will be conducted in Medline, Embase, Cochrane Library, Epistemonikos, Lilacs, CINAHL, PsycINFO, trial registries and grey literature databases without restriction on publication status, year of publication and language. The primary outcomes will be symptoms of aggressive behaviour, quality of life for the individual or their careers, and discontinuation or dropouts/withdrawals of antipsychotics due to adverse events. The secondary outcomes are other not serious adverse events and adherence to pharmacotherapy. Selection, data extraction, and quality assessment will be performed by pairs of reviewers, independently. The Risk of Bias 2 (RoB 2) and Risk of Bias in Non-Randomised Studies of Interventions (ROBINS-I) tools will be used to assess the risk of bias in the included studies. If appropriate, a meta-analysis and network meta-analysis will be conducted to synthesise the results. The overall quality of the evidence for each outcome will be determined by the Recommendation, Assessment, Development and Evaluation approach. Ethics and dissemination This study will systematically summarise the existing evidence evaluating the use of second-generation antipsychotics for treating ASD, in controlled and uncontrolled studies. The results of this review will be disseminated through peer-reviewed publications and conference presentations. PROSPERO registration number CRD42022353795.

[1]  L. Lopes,et al.  Sex differences and adverse events of antiretrovirals in people living with HIV/AIDS: a systematic review and meta-analysis protocol , 2022, BMJ Open.

[2]  E. Madrid,et al.  Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews , 2022, BMJ Evidence-Based Medicine.

[3]  M. Page,et al.  ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis , 2021, BMC Medicine.

[4]  M. Zwahlen,et al.  Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study , 2021, BMC Medical Research Methodology.

[5]  S. Buono,et al.  Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis , 2021, Health and Quality of Life Outcomes.

[6]  X. Jouven,et al.  COVID-19-related medical research: a meta-research and critical appraisal , 2021, BMC Medical Research Methodology.

[7]  L. Lopes,et al.  Pharmaceutical policies: effects of policies regulating drug marketing , 2020, Cochrane Database of Systematic Reviews.

[8]  Claire Glenton,et al.  The TRANSFER Approach for assessing the transferability of systematic review findings , 2020, BMC medical research methodology.

[9]  S. Levy,et al.  Identification, Evaluation, and Management of Children With Autism Spectrum Disorder , 2019, Pediatrics.

[10]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[11]  Tariq M. Alhawassi,et al.  Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis , 2019, Pediatric Drugs.

[12]  J. Barendregt,et al.  A new improved graphical and quantitative method for detecting bias in meta-analysis. , 2018, International journal of evidence-based healthcare.

[13]  Maureen S. Durkin,et al.  Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012 , 2018, Morbidity and mortality weekly report. Surveillance summaries.

[14]  Nicky J Welton,et al.  Network Meta-Analysis for Decision-Making , 2018 .

[15]  N. Team.  Autism spectrum disorder in under 19s: recognition, referral and diagnosis , 2017 .

[16]  Andrew Thomas,et al.  MultiBUGS: A Parallel Implementation of the BUGS Modeling Framework for Faster Bayesian Inference , 2017, J. Stat. Softw..

[17]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[18]  J. McGowan,et al.  PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. , 2016, Journal of clinical epidemiology.

[19]  T. Pringsheim,et al.  Aripiprazole for autism spectrum disorders (ASD). , 2012, The Cochrane database of systematic reviews.

[20]  Deukwoo Kwon,et al.  Simulation-based estimation of mean and standard deviation for meta-analysis via Approximate Bayesian Computation (ABC) , 2015, BMC Medical Research Methodology.

[21]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.

[22]  Rebecca M. Turner,et al.  Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data , 2015, Journal of clinical epidemiology.

[23]  Peter Jüni,et al.  Systematic reviews and meta-analyses of randomized trials: principles and pitfalls , 2014 .

[24]  E. Fombonne,et al.  Aggressive Behavior Problems in Children with Autism Spectrum Disorders: Prevalence and Correlates in a Large Clinical Sample. , 2014, Research in autism spectrum disorders.

[25]  T. Vos,et al.  The epidemiology and global burden of autism spectrum disorders , 2014, Psychological Medicine.

[26]  R. Findling,et al.  A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. , 2014, The Journal of clinical psychiatry.

[27]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  Y. S. Kim,et al.  Global Prevalence of Autism and Other Pervasive Developmental Disorders , 2012, Autism research : official journal of the International Society for Autism Research.

[29]  Simon G Thompson,et al.  Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews , 2012, International journal of epidemiology.

[30]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[31]  E. Fombonne,et al.  Prevalence of Autism Spectrum Disorders in a Total Population Sample , 2011 .

[32]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[33]  Hannah R Rothstein,et al.  A basic introduction to fixed‐effect and random‐effects models for meta‐analysis , 2010, Research synthesis methods.

[34]  R. Findling,et al.  Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder , 2009, Pediatrics.

[35]  R. Mcquade,et al.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[36]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[37]  D. Mandell.  Psychiatric Hospitalization Among Children with Autism Spectrum Disorders , 2008, Journal of autism and developmental disorders.

[38]  M. Aref-Adib,et al.  Risperidone for autism spectrum disorder. , 2007, The Cochrane database of systematic reviews.

[39]  J P T Higgins,et al.  Systematic review of prevalence studies of autism spectrum disorders , 2005, Archives of Disease in Childhood.

[40]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[41]  J. Overall,et al.  Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[42]  R. Perry,et al.  The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children , 1989, Journal of autism and developmental disorders.

[43]  Maureen S. Durkin,et al.  Prevalence and Characteristics of Autism Spectrum Disorder Among 4-Year-Old Children in the Autism and Developmental Disabilities Monitoring Network , 2016, Journal of developmental and behavioral pediatrics : JDBP.

[44]  B. D. da Costa,et al.  Systematic reviews and meta-analyses of randomized trials : principles and pitfalls , 2014 .

[45]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials. , 2013 .

[46]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[47]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) , 2008 .

[48]  M. A. Best.  Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .